This announcement is a separate document:
尤尼泰振青会计师事务所（特殊普通合伙）《关于杭州天目山药业股份有限公司2023年年度报告的信息披露问询函》的回复
Reply to the Inquiry Letter on Information Disclosure of the 2023 Annual Report of Hangzhou Tianmushan Pharmaceutical Co., Ltd. by UniTruston Certified Public Accountants (Special General Partnership).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.